Shine Technologies, a private nuclear fusion company in Wisconsin, has signed an agreement to acquire the SPECT business from Lantheus, which focuses on radiopharmaceuticals. The deal includes the North Billerica, Massachusetts facility that produces Lantheus' SPECT products. Following the announcement, Lantheus' shares rose by 1.6%. The financial terms involve an undisclosed upfront cash payment, a convertible note into Shine preferred stock, and potential earnout milestones. The transaction is expected to finalize by the end of the year, pending customary closing conditions.
Mon, 12 May 2025 10:50:16 GMT | The Pharma Letter